Biotechnology company focused on discovering and developing therapies for heart failure and other cardiovascular diseases.
Tenaya Therapeutics, Inc. is a pioneering biotechnology company dedicated to advancing therapies for heart disease across the United States. Employing cutting-edge approaches in cellular regeneration, gene therapy, and precision medicine, Tenaya Therapeutics focuses on developing transformative treatments for a range of cardiovascular conditions.
At the forefront of its innovative pipeline, Tenaya Therapeutics is developing TN-201, an adeno-associated virus (AAV)-based gene therapy designed to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient mutations in the MYBPC3 gene. Additionally, the company is advancing TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i), targeting heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).
Further bolstering its portfolio, Tenaya Therapeutics is progressing TN-401, another AAV-based gene therapy aimed at treating genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) associated with mutations in the PKP2 gene. The company also focuses on developing innovative gene therapies, including the delivery of the dwarf open reading frame (DWORF) gene for dilated cardiomyopathy (DCM) and a reprogramming program utilizing AAV-based approaches for cardiac regeneration post-myocardial infarction.
Founded in 2016 and headquartered in South San Francisco, California, Tenaya Therapeutics has rapidly emerged as a leader in cardiovascular therapeutics. With a robust pipeline and a commitment to scientific innovation, the company aims to address critical unmet needs in cardiovascular care, ultimately improving outcomes for patients worldwide.